Supplementary material for Ekman et al., A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial, Acta Oncologica, 2015; doi: 10.3109/0284186X.2015.1049290

Supplementary Table I. Summary of exposure of AXL1717 in single dose part, phase Ia.

Dose BID (mg)	No. of single BID treatments (No. of patients)
5	2 (1)
10	1 (1)
20	1 (1)
40	2 (2)
80	2 (2)
120	2 (2)
160	5 (3)
215	4 (4)
290	5 (4)
390	5 (5)
520	6 (6)
700	7 (7)
930	8 (8)
1240	8 (8)
1650	8 (8)
2200	7 (7)
2900	5 (3)

Supplementary Table II. Summary of exposure of AXL1717 in multi-dose part, phase Ib.

Dose BID (mg)	Total number of patients	7-days*	14-days*	21-days*	28-days*
290	1	0 (0)	1 (1)	0 (0)	0 (0)
390	23	2 (2)	4 (4)	5 (5)	18 (12)
520	13	16 (9)	8 (7)	0 (0)	0 (0)
700	7	7 (6)	1 (1)	0 (0)	0 (0)
930	4	5 (4)	1 (1)	0 (0)	0 (0)

*number of treatment periods (number of patients)

Supplementary Table III. Summary of exposure of AXL1717 in the extension study.

Dose BID (mg)	Total number of patients	7-days*	14-days*	21-days*	28-days*
290	2	0 (0)	6 (1)	0 (0)	1 (1)
390	8	0 (0)	4 (1)	1 (1)	16 (6)
520	3	2 (2)	2 (1)	0 (0)	0 (0)
700	0	0 (0)	0 (0)	0 (0)	0 (0)
930	1	0 (0)	11 (1)	0 (0)	0 (0)

*number of treatment periods (number of patients)

Supplementary Table IV. Descriptive statistics for C_{max} and AUC₀₋₁₂ by day of dosing in patients receiving repeated dosing with 390 mg BID or 520 mg BID.

Variable	Dose mg	Day	N	Geometric mean	Min	Max	CV%
C _{max} (nmol/L)	390	1	14	448	127	2153	87.2
	390	7	5	1957	732	6343	85.0
	390	14	10	1783	715	4802	61.0
	390	21	8	1612	355	6405	86.6
	390	28	8	1806	677	3635	53.7
	520	1	23	652	79	2560	81.4
	520	7	23	2519	281	7473	59.0
AUC ₀₋₁₂ (nmol/L*h)	520	14	7	2391	498	6894	66.1
	390	1	14	1877	796	15349	132
	390	7	5	12,921	5330	39,240	81.3
	390	14	10	9982	3091	26,524	64.3
	390	21	8	8448	1416	38,876	94.9
	390	28	8	8471	2960	20,043	58.1
	520	1	23	3142	316	13,614	85.1
	520	7	23	14,424	1462	51,854	69.5
	520	14	7	13,079	1875	33,361	59.7

Supplementary Figure 1. Dose adjusted geometric mean AUCinf after single doses of AXL1717.

Supplementary Figure 2. Concentration-time profiles on Day 1, 7 and 14 of dosing with 520 mg BID in one patient.

Supplementary Figure 3. A and B Levels of S-IGF1 and S-IGFBP3 (ng/mL) were assayed from blood samples from patients treated with AXL1717 for either up to 14 days (sampled at Day 7 or 14) or more than 14 days (sampled at Day 21 or 28). The obtained values were compared with the pre-dose values (at Day 0) for each patient. Due to large variations of S-IGF1 and S-IGFBP3 levels among the patients, the mean differences in values after treatments (≤ 14 days vs. > 14 days) compared to the pre-dose concentrations were calculated. S-IGF1 and S-IGFBP are presented in Supplementary Figure 3A and B, respectively. P-values (Student's t-test) are indicated.